Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
NCT05090566 · Pfizer · PHASE2 · terminated · last registry update 2026-04-24 · Multiple myeloma · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “A business decision was made by Pfizer to terminate the study and not proceed with the Phase 2 expansion of this study. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.” | Open Targets' class: business administrative | Registry record, Pfizer |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD3E in multiple myeloma within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-22Phase 3 first posted: Alliance for Clinical Trials in Oncology, Daratumumab and Recombinant Human Hyaluronidase + Lenalidomide (NCT07887984)
- 2026-10-07Also stopped (suspended): City of Hope Medical Center, Talquetamab (NCT06572605)
- 2026-07-31Phase 3 first posted: Polish Myeloma Consortium, Teclistamab + Talquetamab (NCT07740486)
- 2026-07-27Phase 3 first posted: AbbVie, Etentamig + Pomalidomide (NCT07728188)
- 2026-06-26Phase 3 first posted: University of Heidelberg Medical Center, Teclistamab + Daratumumab (NCT07671287)
- 2026-06-16Phase 3 first posted: University of Leeds, Daratumumab + Lenalidomide (NCT07649525)
- 2026-04-08Phase 3 first posted: Janssen Research & Development, LLC, JNJ-79635322 + Teclistamab (NCT07518186)
- 2025-12-02Phase 3 first posted: Janssen Research & Development, LLC, JNJ-79635322 + Teclistamab (NCT07258511)
- 2025-08-22Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., QLS32015 + Pomalidomide (NCT07138209)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision